Novartis has signed a global licensing agreement with Arrowhead Pharmaceuticals for the preclinical RNA interference (RNAi) therapy ARO-SNCA, targeting alpha-synuclein in Parkinson’s disease and related disorders. The deal, announced Tuesday and reported by Reuters, includes a $200 million upfront payment to Arrowhead, with up to $2 billion in potential milestones, plus tiered royalties (capped in… The post Novartis bets $200M upfront on Arrowhead’s Parkinson’s RNAi, total value up to...| Drug Discovery and Development
© FOOD FOUNDERS Studio FOOD FOUNDERS Studio, ein in Zürich ansässiges Venture-Studio, hat erfolgreich 1,2 Millionen Schweizer Franken (1,5 Millionen Dollar) an Finanzmitteln aufgebracht und sein erstes Projekt offiziell gestartet. Das von Giacomo Cattaneo und Alexandre Morel gegründete Studio konzentriert sich auf die Kommerzialisierung von Lebensmitteltechnologien, die an europäischen Universitäten entwickelt wurden und noch nicht auf den Markt gekommen sind. Das Hauptziel des Studios ...| vegconomist
The subsidiary of India’s Alkem Laboratories brings new jobs to the area along with its first U.S. manufacturing site. The post NJ welcomes Enzene’s $50M biopharma facility in Hopewell appeared first on NJBIZ.| NJBIZ
The oversubscribed seed funding will be used to improve the storage and transportation of life-saving medicines, the company said.| Silicon Republic
Schneider Shorts 22.08.2025 - an obituary for an Italian haematologist, a Spanish guru returns from Bhutan, concerns for Italian cardiologist in Bristol, with an Irish mystery, a setback for Germany's Weltlöwe, retractions issued and rescinded, failed alchemy, and finally, with Church on Friday, again!| For Better Science
Will Vilhelm win a Nobel Prize of his own? And for what?| For Better Science
Heart devices lead medtech’s summer financing surge. This and more in this week’s life sciences update.| The Real Economy Blog
Biotech labs are mining worm chemistry to design medicines that calm the immune system without the risks of live infection.| Freethink
From curing rare diseases to extending lifespans, four biotech founders share how AI is rewriting the future of medicine.| Freethink
Meissner has launched its RMS (Rotary Impeller Mixing Solutions) portfolio, a line of biocontainer mixing assemblies designed for drop-in compatibility with existing bioprocessing equipment. The product line is designed to provide mixing assemblies compatible with industry-standard tanks and existing drive units, without requiring additional hardware or modifications. RMS assemblies use Meissner’s TepoFlex® polyethylene (PE) multi-layer… The post Meissner launches rotary impeller mixing ...| Research & Development World
We live in the age of -omics. We have genomics to study complete sets of DNA. We have proteomics focused on all the proteins within our cells. And we have metabolomics for metabolites like sugars and lipids. Despite their massive reach and intense focus, these fields have blind spots. They’re both in the margins and... The post Exposomics: Holistic health without the snake oil appeared first on Cold Spring Harbor Laboratory.| Cold Spring Harbor Laboratory
When there’s this much courage and innovation in one space, you can almost feel it in the air. It’s an understanding, a sense that everyone here shares the same mission: to improve people’s lives and help make the world a better place. Imagine the possibilities. On November 19, Cold Spring Harbor Laboratory (CSHL) will host...| Cold Spring Harbor Laboratory
Calgary, Alberta, Canada, August 11, 2025 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 142,987 deferred share units (“DSUs”) to two of Marvel’s directors, in lieu of cash payment for directors’ fees.| Marvel Biosciences
Lilly recently reported topline results from the ATTAIN-1 phase-3 trial evaluating orforglipron, a once-daily oral glucagon-like-peptide-1 (GLP-1) receptor agonist for adults with obesity or overweight without diabetes. GLP-1 receptor agonists mimic gut hormones to curb appetite and slow digestion, a mechanism driving the success of therapies from Novo Nordisk (Ozempic for diabetes and Wegovy for… The post Lilly’s oral GLP-1 drug orforglipron achieves 12.4% weight loss in phase 3 trial bu...| Drug Discovery and Development
By Cody Tranbarger, EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC As the biotech industry trudges through its fourth consecutive year of middling performance and sluggish capital markets, corporate governance has become a salient The post A [Prime]r on Stock Option Repricing in Biotech appeared first on LifeSciVC.| LifeSciVC
I dati degli enti di ricerca richiedono una gestione attenta della sicurezza informatica. Scopri di più in questo articolo.| Agenda Digitale
Learn more about why this biotech company is one to watch in the green space! Eco-Cycle’s Zero Waste Hauling and Consulting Services team works with a sizable roster of local businesses to meet their recycling, composting, and hard-to-recycle hauling needs as well as guiding them toward the cutting edge of sustainable best practices. Many of […] The post Business Spotlight: SomaLogic Labs Help Pioneer New Recycling Stream appeared first on Eco-Cycle.| Eco-Cycle
AI agents have moved from pilots to practice: 14% of large enterprises report partial or full deployments and 23% are piloting, according to the “Rise of agentic AI” report from Capgemini. But as adoption ticks up, trust in fully autonomous agents slid from 43% to 27% over the past year. What does that mix mean… The post AI agents are proliferating in pharma, but taming them may be the next frontier appeared first on Drug Discovery and Development.| Drug Discovery and Development
And more biotech news brought to you by The Readout.| STAT
Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.| STAT
In a new study, Nobel laureate David Baker and colleagues detail new methods for targeting undruggable "disordered" proteins.| STAT
Demand for next-generation GLP-1 drugs is fueling a boom in peptide research, prompting companies like Sai Life Sciences to expand capabilities amid a hot market for obesity and diabetes treatments. “The GLP-1 agonists have exploded the peptide field,” said Maneesh Pingle, Ph.D., executive vice president and head of discovery services at Sai Life Sciences, in… The post Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center appeared first on Drug...| Drug Discovery and Development
Schneider Shorts 27.06.2025 – the innocent man of Santa Cruz, the guilty man of Arkansas, a woman and her dogs harassed, a Marquis knighted by King of Spain, with one of Australia’s top…| For Better Science
Genmab, a Danish company focused on developing antibody therapies for patients with cancer, opened a new site in Plainsboro, NJ.| Drug Discovery and Development
It’s Tuesday, July 1, 2025, and we’re back with your daily breakdown of startup and tech funding moves. Today’s deals span early-stage moonshots and late-stage growth bets—from robotics and longevity biotech to climate tech and crypto trading platforms. AI remains the central theme, driving rounds across nearly every sector. Genesis AI launched out of stealth| Tech Startups - Startups and Technology news
Researchers from the Grainger College of Engineering have created a new nanopore sensor for single-biomolecule detection.| Research & Development World
Cellugy's first lab-made ingredient is EcoFLEXY, a powder cellulose-based rheology modifier or substance that improves viscosity.| Beauty Independent
Over 200 GLP1 obesity programs are in development today. More than 300 PD1/PDL1 cancer programs exist. Greater than 150 programs target each of CD19 and KRAS. Therapeutic crowding has ratcheted up the competitive intensity in biotech to new levels. While The post Biotech Wisdom Of The Crowds: Competition And Capitalism appeared first on LifeSciVC.| LifeSciVC
You know when it’s baking and the heat is just bouncing off everything, you step in the shadows and the temperature instantly drops ten degrees? It ain’t sticking around, just bouncing right back. Anyway, I withstood this onslaught for ten minutes at London Bridge station before cramming into a train full of half-cut sweaty football fans and heading home. As the train meandred between the rooftops of Bermondsey, I caught sight of, for no more than half a second, a seagull nesting in a chi...| The Bounding Box
CellChorus®, the dynamic single-cell analysis company™, announced May 2nd that the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) has awarded CellChorus a Small Business Innovation Research (SBIR) Fast-Track grant. The funds will help advance the development of its Time-lapse Imaging Microscopy In Nanowell Grids™ (TIMING™) platform for dynamic […] The post Houston Biotech Wins $2.5 Million Award to Further Single-Cell Analysi...| Healthcare Weekly
A new bacterium identified on the Tiangong space station has surprised the scientific community with its ability to withstand extreme conditions beyond Earth. In fact, the discovery could change the way we understand microbial life in extraterrestrial environments. The strain, named Niallia tiangongensis, was found on the surface of equipment aboard the Chinese orbital module […]| Techoreon
The post Marvel Biosciences to Give Oral Presentation at the Annual IRSF Rett Syndrome Scientific Meeting appeared first on Marvel Biosciences.| Marvel Biosciences
In new research, Xuelin Li, Sijie Wang, Jiajie Xu, and Xiang Zheng find that the involvement of specialized venture capital firms influences a biotech startup’s drug portfolio by focusing research and development on fewer products.| ProMarket
The equity markets have collapsed in 2025, the IPO window is closed, the FDA is in turmoil, the NIH is being gutted… and it’s a great time to start new biotech companies. Why? Because there are so few being created The post Biotech Venture Creation: The Benefits Of Scarcity appeared first on LifeSciVC.| LifeSciVC
The post Marvel Biosciences to File for Orphan Drug Designation with the U.S. FDA for MB-204 as a Treatment for Rett Syndrome appeared first on Marvel Biosciences.| Marvel Biosciences
Cambridge-based TRIMTECH Therapeutics, a BioTech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases,| EU-Startups
Medical Communications (MedComms) might just be the best industry career option out there for scientists who most enjoy the writing/communicating/organising parts of the job, and on 22nd November 2…| Total Internal Reflection
“No paper — I would wager quite heavily that a large percentage, probably over 90% of papers in the public domain, have errors in them. Whether or not they be known, I would suggest th…| For Better Science
There are a number of innovative applications that dry ice is being used for in the medical industry—it doesn't stop at basic refrigeration!| Dry Ice Corp
The week saw a handful of nine-figure rounds, and some at pretty big valuations. That included one large round minting a new unicorn that has developed an AI-powered coding co-pilot.| Crunchbase News
“your scatter gun approach has undermind a process that is undertaken confidentially […] It is sad that you are determined to undermine people’s reputations in the way you do.…| For Better Science
I hope you will watch this incredible short video of my Korean virtual doppelgänger speaking in my voice and with my mannerisms, presenting words I have wri ...| jamiemetzl.com
I've been listening to Hidden Forces with Demetri Kofinas for years now. He's an excellent interviewer with interests in finance, geopolit...| infoproc.blogspot.com
